COVID-19 infection. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: The intervention group will use Iranian standard treatment protocol for COVID-19 in addition to Ivermectin 3 mg oral tablet at a dose of 0.4 mg/kg manufactured by A
Weight 80-5, 24 mg and weight over 80, 0.4 mg/kg. Intervention 2: Control group: In the control group, placebo tablets made by Alborz Daru of Iran with the same shape, color and weight based dose of i
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with positive coronavirus rapid test or RT-PCR Age>5 years Weight >15 kg No treatment with antiviral drugs before and during the study Informed consent for participation
Exclusion criteria
Exclusion criteria: Underlying liver and kidney disease Patients with acquired immunodeficiency Pregnancy and lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in persistent cough. Timepoint: Daily until improvement. Method of measurement: Question from the patient.;Negative RT-PCR result. Timepoint: 6 days after the intervention. Method of measurement: RT-PCR.;The main complaints recovery time. Timepoint: Daily until symptoms resolve. Method of measurement: Checklist containing patient complaints.;Mortality. Timepoint: Daily. Method of measurement: Record in checklist.;Drug side effect (Wheezing, itching, skin rash, edema, and hypotension). Timepoint: Daily. Method of measurement: Question from the patient.;Reduction in tachypnea. Timepoint: Daily. Method of measurement: Medical record.;Oxigen saturation >94%. Timepoint: Daily. Method of measurement: Medical record. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Mohammad Sadegh Rezai
Mazandaran University of Medical Sciences
Outcome results
None listed